HC Wainwright Has Lowered Expectations for Inventiva (NASDAQ:IVA) Stock Price

Key Points

• HC Wainwright lowered its price target on Inventiva to $14 but maintained a Buy rating, implying 261.76% upside from the stock’s current price.
• Analyst sentiment is broadly positive: MarketBeat reports a consensus Buy rating and an average price target of $14.67, though one analyst rates the stock Sell.
• Inventiva shares opened at $3.87, within their 12-month range of $2.82 to $7.29; the clinical-stage biotech is developing lanifibranor, now being evaluated in a Phase 3 trial.

Inventiva (NASDAQ:IVA - Get Free Report) had its target price decreased by equities research analysts at HC Wainwright to $14.00 in a research report issued to clients and investors on Thursday, Benzinga reports. The brokerage presently has a "buy" rating on the stock. HC Wainwright's price objective would indicate a potential upside of 261.76% from the stock's current price.

IVA has been the topic of several other research reports. Truist Financial lifted their price target on shares of Inventiva from $13.00 to $18.00 and gave the stock a "buy" rating in a research note on Friday, October 2nd. Weiss Ratings upgraded Inventiva from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Friday, October 23rd. Piper Sandler reaffirmed an "overweight" rating on shares of Inventiva in a report on Wednesday, September 16th. Guggenheim raised their target price on Inventiva from $11.00 to $14.00 and gave the stock a "buy" rating in a report on Tuesday, September 15th. Finally, Cantor Fitzgerald initiated coverage on Inventiva in a research report on Friday, July 17th. They set an "overweight" rating on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus target price of $14.67.

Inventiva Price Performance

IVA opened at $3.87 on Thursday. The company's 50 day moving average is $3.77 and its 200 day moving average is $4.86. Inventiva has a 12-month low of $2.82 and a 12-month high of $7.29.

Inventiva (NASDAQ:IVA - Get Free Report) last announced its earnings results on Friday, August 14th. The company reported ($0.14) EPS for the quarter. The business had revenue of $0.75 million for the quarter. Equities analysts forecast that Inventiva will post -0.79 earnings per share for the current year.

Hedge Funds Weigh In On Inventiva

Several large investors have recently added to or reduced their stakes in the company. Commonwealth Equity Services LLC lifted its holdings in Inventiva by 7.0% during the third quarter. Commonwealth Equity Services LLC now owns 89,853 shares of the company's stock valued at $332,000 after purchasing an additional 5,857 shares in the last quarter. Platt Investment Counsel LLC purchased a new stake in shares of Inventiva in the third quarter worth $45,000. China Universal Asset Management Co. Ltd. increased its stake in shares of Inventiva by 78.7% in the third quarter. China Universal Asset Management Co. Ltd. now owns 38,600 shares of the company's stock worth $142,000 after purchasing an additional 17,000 shares in the last quarter. Engineers Gate Manager LP increased its stake in shares of Inventiva by 155.5% in the second quarter. Engineers Gate Manager LP now owns 71,116 shares of the company's stock worth $269,000 after purchasing an additional 43,280 shares in the last quarter. Finally, Seven Fleet Capital Management LP bought a new stake in shares of Inventiva during the 1st quarter valued at $1,111,000. Hedge funds and other institutional investors own 19.06% of the company's stock.

About Inventiva

Inventiva SA is a clinical-stage biopharmaceutical company headquartered in Daix, France. Founded in 2011, the company focuses on developing oral treatments for metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease associated with metabolic disorders.

Inventiva's lead drug candidate is lanifibranor, an investigational pan-peroxisome proliferator-activated receptor (pan-PPAR) agonist being evaluated in the Phase 3 NATiV3 clinical trial.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.